5-Amino-1MQ 50mg is an NNMT inhibitor used primarily to support fat loss and boost metabolism by increasing cellular NAD+ levels. Each vial contains 50mg.
FormatLyophilized Vial
ConcentrationDependent on reconstitution with BAC water
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
5-Amino-1MQ (5 Amino 1 methylquinolinium) is a selective small molecule inhibitor of nicotinamide N-methyltransferase (NNMT); an enzyme that plays a central regulatory role in cellular energy metabolism, adipogenesis, and the methionine cycle. Hudson Science’s formulation supplies 50mg as a lyophilized powder requiring reconstitution prior to use, a format that preserves compound stability and ensures consistent potency across storage and handling conditions for this emerging class of metabolic research compound.
NNMT catalyses the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing S-adenosylhomocysteine (SAH) and 1 methylnicotinamide as byproducts. By selectively inhibiting NNMT, 5-Amino-1MQ increases the intracellular SAM to SAH ratio — elevating the methyl donor availability that drives downstream methylation reactions across multiple metabolic pathways. This shift in the SAM/SAH ratio has downstream effects on NAD+ biosynthesis, sirtuin enzyme activation, and mitochondrial biogenesis — a cascade of metabolic pathway interactions that has positioned NNMT inhibition as one of the more actively researched targets in obesity, metabolic syndrome, and cellular energy homeostasis research.
5-Amino-1MQ’s documented influence on adipocyte biology is a central focus of the current research literature. NNMT is highly expressed in adipose tissue and has been identified as a key regulator of adipogenesis and fat cell size. Selective inhibition has been associated with suppression of adipocyte differentiation, reduction in lipid accumulation, and upregulation of energy expenditure in preclinical models. Its selectivity for NNMT over related methyltransferase enzymes makes it a valuable tool compound in research isolating NNMT’s specific contribution to metabolic regulation from broader methyltransferase activity.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and Hudson Science’s 5-Amino-1MQ meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized powder at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside NAD+ precursor compounds in metabolic pathway and energy homeostasis studies. Browse CSD’s full peptide and research compound range for complete sourcing.
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small molecule NNMT (Nicotinamide N-methyltransferase) inhibitor, targeting one of the most significant metabolic enzymes implicated in obesity, adipogenesis, and cellular energy regulation. NNMT consumes SAM (S-adenosylmethionine) to methylate nicotinamide. Depleting the methyl donor pool and reducing NAD+ precursor availability, while simultaneously promoting fat cell differentiation and lipid accumulation. By inhibiting NNMT, 5-Amino-1MQ is researched for its ability to reduce adipogenesis and fat cell size, increase NAD+ and SAM availability for cellular energy and methylation reactions, enhance metabolic rate through brown adipose tissue activation, reduce body fat without caloric restriction in animal models, and improve insulin sensitivity through metabolic reprogramming of adipose tissue.
5-Amino-1MQ and GLP-1 agonists address fat loss through completely distinct mechanisms. GLP-1 agonists such as Semaglutide act centrally to suppress appetite and reduce caloric intake. Producing fat loss primarily through negative energy balance. 5-Amino-1MQ acts directly on adipose tissue metabolism, inhibiting NNMT to reduce fat cell differentiation, decrease lipid accumulation, and increase intrinsic metabolic rate through NAD+ pathway restoration and brown adipose tissue activation. Critically, animal research demonstrates meaningful fat mass reduction with 5-Amino-1MQ without appetite suppression or caloric restriction; suggesting a fundamentally different and complementary mechanism to GLP-1 agonism that makes the two compound classes potentially synergistic in combination fat loss research protocols.
Reconstitute the 50mg lyophilized vial with bacteriostatic water, add BAC water slowly along the glass wall of the vial, swirl gently to dissolve, do not shake. Adding 5mL of BAC water produces 10mg per mL at this concentration, 0.5mL delivers 5mg and 1mL delivers 10mg per administration. Common research doses range from 5–50mg per administration depending on the research protocol and subject weight. The 50mg vial provides 5–10 research administrations at typical doses, sufficient for initial protocol assessment before sourcing larger quantities for extended research cycles.
5-Amino-1MQ research outcomes focus on adipose tissue metabolism and systemic metabolic parameters. Primary research endpoints include fat mass reduction measured by body composition analysis, adipocyte size reduction in visceral and subcutaneous adipose tissue, NAD+ and SAM level restoration in adipose and hepatic tissue, brown adipose tissue activation through UCP 1 upregulation, insulin sensitivity improvement through adipose tissue metabolic reprogramming, and plasma lipid profile changes. Animal research has demonstrated significant visceral fat reduction with 5-Amino-1MQ administration without body weight matched caloric restriction; a finding that has driven significant research interest in NNMT inhibition as a novel fat loss target independent of appetite suppression pathways.
Yes! This batch has been independently HPLC tested by an accredited third party laboratory confirming compound identity as 5-Amino-1MQ and content accuracy at 50mg per vial. A certificate of analysis is available.
